Bengaluru, January 2026: 4baseCare, a genomics-led precision oncology startup, has raised ₹90 crore (approximately $9.8 million) in the first close of its Series B funding round, co-led by investors Ashish Kacholia and Lashit Sanghvi. Existing investor Yali Capital also participated in the round.
The funding marks a significant milestone for the company after a two-year gap. In 2024, 4baseCare had raised $6 million in Series A funding, led by Yali Capital with participation from Infosys, to strengthen its genomics-driven cancer care platform.
Expanding Genomics-Led Cancer Care Globally
4baseCare plans to deploy the fresh capital to expand its hospital-linked genomics laboratory network across India, the Middle East, Southeast Asia, Latin America, and Central Asia. The company will also scale its AI-powered precision oncology platform, OncoTwin, which supports oncologists with data-backed clinical decision-making for personalised cancer treatment.
Founded by Hitesh Goswami, 4baseCare focuses on building population-relevant clinico-genomic datasets that address the lack of representation of non-Western populations in global cancer research. By integrating genomic testing with real-world clinical and outcomes data, the platform generates actionable insights tailored to regional genetic variations.
OncoTwin Gains Global Recognition
4baseCare’s flagship platform, OncoTwin, was recently selected for the MSK iHub program at Memorial Sloan Kettering Cancer Center, one of the world’s leading cancer research institutions. The selection highlights the platform’s potential to improve treatment accuracy and outcomes in precision oncology.
The company works closely with hospitals to embed genomics-led cancer diagnostics directly into clinical workflows, enabling oncologists to access timely, data-driven insights within hospital settings.
Riding the Momentum in Oncology Innovation
Investor interest in oncology-focused startups has accelerated in recent years, driven by advances in genomics, AI, and personalised medicine. In 2025, Everhope Oncology raised $10 million in seed funding, while MOC Cancer Care & Research Centre secured $18 million in a round led by Elevation Capital. Other emerging players such as ErlySign, OnCare, and OneCell Diagnostics have also attracted investor backing.
With its focus on underserved populations and emerging markets, 4baseCare is positioning itself as a key player in the next phase of precision oncology and genomics-led cancer care.
As cancer incidence rises globally and the demand for personalised treatment grows, 4baseCare’s expansion across multiple geographies could play a pivotal role in improving access to data-driven, population-specific cancer diagnostics and therapy selection.
Ruchi Kumar is the associate editor at Entrepreneur News Network and TVW News India, where she leads editorial strategy, brand storytelling, and startup ecosystem coverage. With a strong focus on innovation, business, and marketing insights, he curates impactful narratives that spotlight India’s evolving entrepreneurial landscape.